June 12, 2025 — It is undeniable that obesity is a complex, chronic disease. When we gather people from all over the world who understand obesity, this is the number one thing everyone can agree upon. And yet, when we sit down to talk about models for health systems delivering obesity care, it is more likely that folks who […]
May 27, 2025 — “It’s absolutely insane to try to keep up with it all,” says obesity medicine physician Laura Davisson. She is talking about the impossible maze of requirements that so-called health insurance plans set up to prevent people from securing coverage for medicines to treat obesity. It leads us to ask: Are health plans insuring profits more […]
May 22, 2025 — The game is over. Today is the day legal semaglutide compounding at scale ends by decree from the FDA. Compounding pharmacies have known this day was coming since February when the agency determined that the shortage of semaglutide from Novo Nordisk was over. Well-informed patients who have depended upon compounding for affordable access to a […]
May 20, 2025 — A new viewpoint in JAMA Pediatrics articulates a concern we hear repeatedly about the Lancet Commission on Clinical Obesity. Pediatric obesity experts have reservations about applying the concept of preclinical obesity in pediatrics. Melania Manco is a professor of pediatrics, clinical research scientist, and consultant endocrinologist at the Bambino Gesù Hospital in Rome. She writes: […]
April 30, 2025 — Mass market compounding of semaglutide and tirzepatide is pretty much a thing of the past. As that chapter in the story of inadequate access to care closes, it seems that Novo Nordisk is ready to go all in with telehealth deals to make up some lost ground. Their press release spells it out: “Today, Novo […]
April 28, 2025 — Happy headlines late last year told us that obesity recently “dipped” in the U.S., perhaps because of medicines like semaglutide and tirzepatide. Those headlines presented a partial and misleading truth that a new analysis in Lancet Diabetes & Endocrinology explains more fully. Yes, the prevalence of overweight and mild obesity has seemingly plateaued. But this […]
April 23, 2025 — ICER, the Institute for Clinical and Economic Review, yesterday brought a sharp focus to the challenge of dealing with the money flowing for obesity medicines. Sarah Emond, ICER’s CEO, explained the challenge and the opportunity of this unique moment: “This new class of obesity medicines offers weight reduction and associated benefits that, if they’re sustained […]
April 14, 2025 — The first update to Canadian guidelines for pediatric obesity in two decades is out today. The authors grounded them in the best available science. They crafted them with the values of children and families at the center of their process. In short, these are very solid guidelines. But there’s just one little problem. The scarce […]
April 5, 2025 — We should be used to this by now. For years, we’ve urged policymakers to find a way out of the box that has Medicare denying coverage for obesity. This time, it seemed we were close. But close doesn’t count. Late yesterday, the Trump administration said “CMS is not finalizing” provisions of a proposed rule that […]
March 31, 2025 — A new interview with ConscienHealth founder Ted Kyle offers a long view of more than two decades of work on obesity. The interview explores a core question that people ask all the time: Are we making progress in flipping the script on obesity? Or are we still fighting the same misunderstanding of obesity that has […]
